Controversy

Status:Open

Will Annual Global Sales of GLP-1-Based Anti-Obesity and Diabetes Drugs Exceed $100B by 2028?

Discuss on

UNLIKELYLIKELY

Claims

Last Updated 3 days ago

Fortune Business Insights"The global anti-obesity drugs market size was valued at USD 4.51 billion in 2023 and is projected to grow from USD 6.15 billion in 2024 to USD 37.94 billion by 2032, exhibiting a CAGR of 25.5% during the forecast period (2024-2032)."Nov 10, 2025

Fortunebusinessinsights

Gabelli"We estimate about 12-15 million patients will be using GLP-1 drugs by 2030 across both indications, which translates to the market growing from ~$30B today to ~$80B by 2030."Apr 01, 2025

Gabelli

J.P. Morgan"J.P. Morgan Global Research forecasts that the global incretin market, which includes GLP-1s, will reach $200 billion by 2030."

Goldman Sachs"Goldman Sachs Research forecasts the global market to reach $95 billion by 2030 — lower than its previous estimate of $130 billion."

UBS Global Wealth Management"This [GLP-1 model forecast] translates into $126bn sales by 2029, a 2023-2029 sales CAGR of 30%."Nov 26, 2025

Ubs

Teneo"Analysts project the global GLP-1RA market to reach between $75bn and $140bn by 2030."Jul 06, 2026

Teneo

CNBC"Wall Street is betting big on the burgeoning industry, with estimates suggesting it could be worth upwards of $100 billion by 2030."

Inizio Ignite"The U.S. obesity market alone is expected to exceed $100 billion by 2030."

"TD Cowen has lifted its global GLP-1 sales forecast to $150 billion by 2030."

"The market is projected to reach USD 70.08 billion in 2025 and USD 156.71 billion by 2030."

Grand View Research"The global GLP-1 agonists weight loss drugs market size was estimated at USD 13.84 billion in 2024 and is projected to reach USD 48.84 billion by 2030, growing at a CAGR of 18.54% from 2025 to 2030."Nov 26, 2025

Grandviewresearch

BCC Research"According to BCC Research’s Global GLP-1 Analogues Market report, the market was valued at $54.8 billion in 2024 and is projected to reach $268.4 billion by 2030."

Research and Markets"The global market for GLP-1 Receptor Agonist was valued at US$51.9 Billion in 2024 and is projected to reach US$137.4 Billion by 2030."

TD Securities"Global GLP-1 sales in 2030 could reach US$139 billion, up from our US$101 billion forecast a little over a year ago."Nov 26, 2025

TD Securities

Edgen"The obesity therapeutics market is projected for significant expansion, targeting $20.84 billion by 2033 with a compound annual growth rate of 20.6%."Nov 26, 2025

Edgen

Harvest ETFs"The GLP-1 drug class boasts projected sales exceeding US $150 billion by 2030."

Len Yaffe"I Forecast the US 2030 Anti-Obesity Drug Market to Approximate $150 Billion."

UPS Healthcare"The global GLP-1 market is projected to exceed $100 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.6%."

GlobalData"By 2031, GlobalData expects the obesity market to grow at a strong compound annual growth rate (CAGR) of 32.3%, reaching sales of $173.5 billion by the end of the forecast period."